Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Sep;90(9):995-8.
doi: 10.1136/hrt.2003.028811.

Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II)

P W Serruys  1 , P A Lemos, B A van Hout; Arterial Revascularisation Therapies Study part II Steering Committee and Investigators
Affiliations
Clinical Trial

Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II)

P W Serruys et al. Heart. 2004 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of major adverse cardiac events (death, myocardial infarction, or repeat revascularisation) at six months for patients with multivessel disease treated with sirolimus eluting stents (SES) or bare metal stents (control). The incidence of repeat revascularisation during follow up is shown below.
See this image and copyright information in PMC

References

    1. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117–24. - PubMed
    1. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184–9. - PubMed
    1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–80. - PubMed
    1. Degertekin M , Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610–3. - PubMed
    1. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes—insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093–9. - PubMed

MeSH terms